Lassa Fever: Is This Why the World Health Organization Said There Would Be 10,000 New Cases of Ebola a Week by December?

Lizzie Bennett
Underground Medic

 The symptoms are identical to those of Ebola. Fever, vomiting and bleeding all occur. Lassa, unlike Ebola is spread by infected rats, but once it has infected people human to human transmission begins. Like Ebola patients, those suffering from Lassa need to be treated in strict isolation.

Ebola is not the only haemorrhagic fever that stalks West Africa. The Lassa season is about to begin. This year, like every year, around 20,000 people will succumb to the disease in the region.

Lassa fever is spread by contact with bodily secretions of infected people as well as by inhalation of the dust from dried rat faeces. There is some evidence that supports the sporadic spread of the disease via infected rat bites.

Like Ebola, not everyone dies from Lassa. Usually, the death rate is much lower than it is with Ebola, but there have been sporadic outbreaks where the death rate has reached 70%, albeit rarely.

Every year medics and scientists struggle to contain Lassa; it’s a major focus for what health services there are in the region. This year however that focus has been taken by Ebola. Wards and medical facilities usually set aside for Lassa patients have been overwhelmed by those suffering from Ebola. Dr. Sheik Umar Khan head of the Lassa programme at Kenema Government Hospital, Sierra Leone died of Ebola in September. Six nurses and a lab technician have also been lost to the disease leaving the specialist unit direly understaffed.

This situation causes two major problems. Firstly, cases of Lassa will go untreated causing a surge in deaths from the disease. Secondly, people may assume they are suffering from Lassa because of its prevalence at this time of year, when in fact they are suffering from and spreading, Ebola.

At this point in the Ebola epidemic there is little point waiting for laboratory confirmation of the disease. The fact is that with both Lassa and Ebola showing the same symptoms, and with both diseases requiring treatment in isolation, the tipping point has arrived.

There is no way the already overwhelmed medical facilities are going to be able to cope with the extra case load. The countries worst hit by Ebola are the same countries that suffer the worst outbreaks of Lassa Fever.

Ribavirin is used to treat Lassa, but is useless against Ebola. Giving every patient Ribavirin and waiting to see what happens is not an option. On average there are 300,000-500,000 cases of Lassa Fever every year in West Africa, all of them presenting with the same symptoms as Ebola. (source)

There is no possibility whatever that all of these people, or even half of them can be treated, let alone isolated. The toll that Lassa takes on West Africa this year remains to be seen, but it wouldn’t be a surprise if it’s worse than usual given the lack of facilities for patients. Every coin, though, has two sides, and if Lassa patients aren’t being treated, then neither are Ebola patients. It’s inevitable that there will be confusion amongst medical staff about who has what condition.

One has to wonder if it was the pending Lassa season that made the World Health Organization suggest that the death rate ‘from Ebola’ would massively increase in the latter part of this year. They predicted up to 10,000 cases a week by December. If you add Lassa Fever cases to the current rate of Ebola cases being reported that would be about right.

With the projected number of isolation beds available in Sierra Leone, Liberia and Guinea coming in at 4,500 by December 1st, which disease patients are suffering from is a moot point…They can’t be isolated regardless of what it is.

Nigeria, declared Ebola free just last week, is reporting an outbreak of Lassa in Oyo State. Medeciens Sans Frontieres (MSF) has already lost one doctor to Lassa according to Dr Geraldine O’Hara, an infectious diseases specialist from Huddersfield, UK.

It would be insane to think that these diseases are just Africa’s problem – it isn’t. As we saw with Thomas Duncan, it only takes one infected person to slip through the net and the chain of infection starts all over again in a new place. Luckily, this time it was contained; next time who knows?

– See more at: http://www.thedailysheeple.com/lassa-fever-is-this-why-the-world-health-organization-said-there-would-be-10000-new-cases-of-ebola-a-week-by-december_112014#sthash.cwDkptlC.dpuf

What is Lassa fever?

Lassa fever is an acute viral illness that occurs in West Africa. The illness was
discovered in 1969 when two missionary nurses died in Nigeria, West Africa. The
cause of the illness was found to be Lassa virus, named after the town in Nigeria
where the first cases originated. The virus, a member of the virus family
Arenaviridae, is a single-stranded RNA virus and is zoonotic, or animal-borne.
In areas of Africa where the disease is endemic (that is, constantly present), Lassa
fever is a significant cause of morbidity and mortality. While Lassa fever is mild or
has no observable symptoms in about 80% of people infected with the virus, the
remaining 20% have a severe multisystem disease. Lassa fever is also associated
with occasional epidemics, during which the case-fatality rate can reach 50%.
Where is Lassa fever found?
Lassa fever is an endemic disease in portions of West Africa. It is recognized in
Guinea, Liberia, Sierra Leone, as well as Nigeria. However, because the rodent species which carry the virus are
found throughout West Africa, the actual geographic range of the disease may extend to other countries in the
region.
How many people become infected?
The number of Lassa virus infections per year in West Africa is estimated at 100,000 to 300,000, with approximately
5,000 deaths. Unfortunately, such estimates are crude, because surveillance for cases of the disease is not
uniformly performed. In some areas of Sierra Leone and Liberia, it is known that 10%-16% of people admitted to
hospitals have Lassa fever, which indicates the serious impact of the disease on the population of this region.
In what animal host is Lassa virus maintained?
The reservoir, or host, of Lassa virus is a rodent known as the “multimammate rat” of the genus Mastomys. It is not
certain which species of Mastomys are associated with Lassa; however, at least two species carry the virus in Sierra
Leone. Mastomys rodents breed very frequently, produce large numbers of offspring, and are numerous in the
savannas and forests of West, Central, and East Africa. In addition, Mastomys generally readily colonize human
homes. All these factors together contribute to the relatively efficient spread of Lassa virus from infected rodents to
humans.
How do humans get Lassa fever?
There are a number of ways in which the virus may be transmitted, or spread, to humans. The Mastomys rodents
shed the virus in urine and droppings. Therefore, the virus can be transmitted through direct contact with these
materials, through touching objects or eating food contaminated with these materials, or through cuts or sores.
Because Mastomys rodents often live in and around homes and scavenge on human food remains or poorly stored
food, transmission of this sort is common. Contact with the virus also may occur when a person inhales tiny particles
in the air contaminated with rodent excretions. This is called aerosol or airborne transmission. Finally, because
Mastomys rodents are sometimes consumed as a food source, infection may occur via direct contact when they are
caught and prepared for food.
Lassa fever may also spread through person-to-person contact. This type of transmission occurs when a person
comes into contact with virus in the blood, tissue, secretions, or excretions of an individual infected with the Lassa
virus. The virus cannot be spread through casual contact (including skin-to-skin contact without exchange of body
fluids). Person-to-person transmission is common in both village and health care settings, where, along with the
above-mentioned modes of transmission, the virus also may be spread in contaminated medical equipment, such as
reused needles (this is called nosocomial transmission).What are the symptoms of Lassa fever?
Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus.
These include fever, retrosternal pain (pain behind the chest wall), sore throat, back pain, cough, abdominal pain,
vomiting, diarrhea, conjunctivitis, facial swelling, proteinuria (protein in the urine), and mucosal bleeding.
Neurological problems have also been described, including hearing loss, tremors, and encephalitis. Because the
symptoms of Lassa fever are so varied and nonspecific, clinical diagnosis is often difficult.
How is the disease diagnosed in the laboratory?
Lassa fever is most often diagnosed by using enzyme-linked immunosorbent serologic assays (ELISA), which
detect IgM and IgG antibodies as well as Lassa antigen. The virus itself may be cultured in 7 to 10 days.
Immunohistochemistry performed on tissue specimens can be used to make a post-mortem diagnosis. The virus
can also be detected by reverse transcription-polymerase chain reaction (RT-PCR); however, this method is
primarily a research tool.
Are there complications after recovery?
The most common complication of Lassa fever is deafness. Various degrees of deafness occur in approximately
one-third of cases, and in many cases hearing loss is permanent. As far as is known, severity of the disease does
not affect this complication: deafness may develop in mild as well as in severe cases. Spontaneous abortion is
another serious complication.
What proportion of people die from the illness?
Approximately 15%-20% of patients hospitalized for Lassa fever die from the illness. However, overall only about
1% of infections with Lassa virus result in death. The death rates are particularly high for women in the third
trimester of pregnancy, and for fetuses, about 95% of which die in the uterus of infected pregnant mothers.
How is Lassa fever treated?
Ribavirin, an antiviral drug, has been used with success in Lassa fever patients. It has been shown to be most
effective when given early in the course of the illness. Patients should also receive supportive care consisting of
maintenance of appropriate fluid and electrolyte balance, oxygenation and blood pressure, as well as treatment of
any other complicating infections.
What groups are at risk for getting the illness?
Individuals at risk are those who live or visit areas with a high population of Mastomys rodents infected with Lassa
virus or are exposed to infected humans. Hospital staff are not at great risk for infection as long as protective
measures are taken.
How is Lassa fever prevented?
Primary transmission of the Lassa virus from its host to humans can be prevented by avoiding contact with
Mastomys rodents, especially in the geographic regions where outbreaks occur. Putting food away in rodent-proof
containers and keeping the home clean help to discourage rodents from entering homes. Using these rodents as a
food source is not recommended. Trapping in and around homes can help reduce rodent populations. However, the
wide distribution of Mastomys in Africa makes complete control of this rodent reservoir impractical.
When caring for patients with Lassa fever, further transmission of the disease through person-to-person contact or
nosocomial routes can be avoided by taking preventive precautions against contact with patient secretions (together
called VHF isolation precautions or barrier nursing methods). Such precautions include wearing protective clothing,
such as masks, gloves, gowns, and goggles; using infection control measures, such as complete equipment
sterilization; and isolating infected patients from contact with unprotected persons until the disease has run its
course.
What needs to be done to address the threat of Lassa fever?
Further educating people in high-risk areas about ways to decrease rodent populations in their homes will aid in the
control and prevention of Lassa fever. Other challenges include developing more rapid diagnostic tests and
increasing the availability of the only known drug treatment, ribavirin. Research is presently under way to develop a
vaccine for Lassa fever.

US Department of Defence (USAMRIID) & Tulane University Released This Bioengineered Airborne Ebola/Lassa Hybrid in Sierra Leone

http://www.freerepublic.com/

The primary Ebola strain being spread right now (as their are 2) was bioengineered by the US Department of Defense (via USAMRIID) & Tulane University with the knowledge/help from pharma/biotech giants such as Monsanto, Alnylam, Bristol-Myers Squibb, Merck, Pfizer and a much smaller pharma company based out of Canada called Tekmira. A known Ebola strain from Central-Africa was used as the base, and was bioengeneered to become a new hybrid respiratory illness (a combination of Ebola Virus & Lassa Hemorrhagic Fever, weaponized via Tulane University & USAMRIID at Fort Detrick) making it become a genetic variant of the original strain. This bioengineered hybrid allowed for airborne human-to-human transmission, an extended incubation period (to increase spread/threat), and a slightly toned down virility (to have the ideal initial wanted mortality rate (~40%)).

Ebola (EBOV) – Human-to-human transmission occurs via direct contact with blood or bodily fluids from an infected person (including embalming of an infected dead person) or by contact with contaminated medical equipment, particularly needles and syringes.
[link to www.msdsonline.com]
Lassa (LASV) – Inhalation of tiny particles of infective material (aerosol) is believed to be the most significant means of exposure.
[link to www.cdc.gov]
Ebola/Lassa (EBOV/LASV) – Human-to-human transmission occurs via direct contact with blood or bodily fluids AND/ORInhalation of tiny particles of infective material (aerosol) from an infected person (including embalming of an infected dead person) or by contact with contaminated medical equipment, particularly needles and syringes.

Ebola Virus was chosen as the base virus for the hybrid due to its high mortality rate and other ideal bio-warfare properties.

Filoviruses like Ebola have been of interest to the Pentagon since the late 1970s, mainly because Ebola and its fellow viruses have high mortality rates — in the current outbreak, roughly 60 percent to 72 percent of those who have contracted the disease have died — and its stable nature in aerosol make it attractive as a potential biological weapon.
[link to www.navytimes.com]

The Sierra Leone Ebola hybrid strain (EBOV/LASV, ~40% mortality rate) is shown to have a lower mortality rate then the Guinea Ebola strain (ZEBOV, ~75% mortality rate), but is shown to instead be MUCH more human-to-human transmittable, due to it being an airborne hybrid. Basically there are 2 strains going on at the same time (75% Mortality – Ebola-Zaire) & (40% Mortality, Ebola/Lassa, airborne)).

Volume 20, Number 7—July 2014: Undiagnosed Acute Viral Febrile Illnesses, Sierra Leone
PRNT results indicated that the infecting virus was most closely related to EBOV, except for 1 SUDV-reactive patient sample. This finding was unexpected because our assumption was that any ebolavirus would more likely be TAFV, the only species described in West Africa. Although the serum samples were able to neutralize EBOV only at a low level (1:40 dilution), it is possible that the virus is an EBOV genetic variant.
[link to wwwnc.cdc.gov]

July 31, 2014 Stats
Guinea = 339/460 = ~73% mortality rate = ~5-9 day incubation = Ebola-Zaires (natural Ebola-Zaire)
Sierra Leone = 233/533 = ~43% mortality rate = ~9-21 day incubation = Ebola/Lassa (bioengineered hybrid, airborne)
[link to www.ibtimes.com]

Because of these tweaks, the current strain of Ebola we should be worried about is actually a “respiratory virus” unlike any other Ebola strains that were previously known (as it is a bioengineered/weaponized hybrid). Because the US knows this airborne strain is a respiratory virus (the one that will develop into the actual Pandemic), they needed to make some last minute adjustments to their emergency pandemic protocols, which were just refined on July 31, 2014 by Barack Obama to suite the needed definition in preparation for a WHO Pandemic Level 6 Declaration (down the line).

April 4, 2003 – Executive Order — Revised List of Quarantinable Communicable Diseases
(b) Severe Acute Respiratory Syndrome (SARS), which is a disease associated with fever and signs and symptoms of pneumonia or other respiratory illness, is transmitted from person to person predominantly by the aerosolized or droplet route, and, if spread in the population, would have severe public health consequences.
[link to www.gpo.gov]

VS (just revised by Obama)…

July 31, 2014 – Executive Order — Revised List of Quarantinable Communicable Diseases
“(b) Severe acute respiratory syndromes, which are diseases that are associated with fever and signs and symptoms of pneumonia or other respiratory illness, are capable of being transmitted from person to person, and that either are causing, or have the potential to cause, a pandemic, or, upon infection, are highly likely to cause mortality or serious morbidity if not properly controlled. This subsection does not apply to influenza.”
[link to www.whitehouse.gov]

This bioengineered “respiratory” variation of the Ebola virus (EBOV/LASV) was then released via the Kenema Government Hospital Lassa Diagnostic Laboratory (Soros / Gates Foundation) in Sierra Leone by USAMRIID/Tulane University earlier this year, which used unwitting Lassa Fever Program subjects as hosts (which were made immune-carriers to the new hybrid virus they then unknowingly spread) as part of a Tulane University “Ebola testing” project being held in 3 regions of Africa (Sierra Leone, the Republic of Guinea, and Liberia).

Manual of Security Sensitive Microbes and Toxins
Security sensitive microbes (viruses, bacteria, fungi, and parasites) and toxins, which are often referred to as the select agents and toxins, have the capacity to cause serious illness and death in humans, animals, and plants. Throughout history, these microbes and toxins have been exploited in one form or another as biowarfare and bioterror agents that create fear and panic well beyond any actual physical damages they might cause.
[link to books.google.ca]

Tulane University Biosafety Plan
Select Agents (SA) – Biological agents that may be used for the purposes related to bioterrorism and which are thus regulated by the Select Agent Program (42 CFR Part 72).
[link to tulane.edu (secure)]

Lassa Fever Program
Tulane University has a long-standing partnership with the Lassa Fever Program at the KGH. When it was established in 2004, Tulane was contracted as the principle implementing partner of the Mano River Unione Lassa Fever Network program (MRU-LFN), a diverse group of organizations working together to develop national and regional prevention and control strategies for Lassa Fever, as well as focusing on building the capacity of the laboratory at the hospital. Since then, the work conducted by Tulane and its partners at KGH has grown to include new lines of research and public health surveillance.
[link to vhfc.org]

Ministry of Health and Sanitation, Sierra Leone
July 23 – Tulane University to stop Ebola testing during the current Ebola outbreak.
[link to www.facebook.com (secure)]

Bill Gates & George Soros Funding The Bioweapons Lab At The Focus of Ebola Outbreak
[link to www.youtube.com]

Which brings us to Tekmira, which is heavily funded by the U.S. Army Medical Research Institute of Infectious Diseases (via the United States Department of Defence)…

Tekmira doses first subject in human clinical trial of TKM-Ebola
Tekmira Pharmaceuticals Corporation has dosed the first subject in a Phase 1 human clinical trial of TKM-Ebola, an anti-Ebola viral therapeutic that is being developed under a US$140 million contract with the U.S. Department of Defense.
[link to biotechnologyfocus.ca]

With Monsanto invested heavily as well (just a small sample of Monsanto funding)…

Tekmira Receives $1.5 Million Milestone Payment
Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has received a $1.5 million milestone payment from Monsanto following completion of specified program developments.
[link to finance.yahoo.com]

And Tekmira has partnerships with some of the biggest players in the pharmaceutical industry…

In addition to its pipeline of products, Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam, Pfizer, Takeda, Bristol-Myers Squibb, and Merck.
[link to www.ic.gc.ca]

And Tekmira (the little guy being backed by the big guys (aka a front)) is currently the leading pharmaceutical company being pushed as the best chance for the Ebola cure, as they already start hyping that this strain will get out of control…

Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
Monsanto and Dept. of Defense help fund pharma company that could earn billions from Ebola treatment
[link to www.naturalnews.com]

Because of this they are going to be holding more clinical human TKM-Ebola trials very shortly in an attempt to rush an Ebola cure…

Experimental Ebola vaccine will be tested on people NEXT MONTH as U.S. pushes clinical trial of possible life-saving drug
The U.S government will begin testing an experimental ebola vaccine on humans as early as next month, it has been reported.
The drug, which is currently being developed, has seen positive results in clinical trials when used to treat primates.
It has prompted the U.S. government to move towards testing the possible life-saving vaccine on people for the first time, USA Today said.
The National Institutes of Health’s infectious disease unit has been working with the Food and Drug Administration to put the vaccine through trials as quickly as possible, according to the report.
[link to www.dailymail.co.uk]

I love how it says the U.S Government will BEGIN human trails… when the first DoD funded TKM-Ebola trails using the same company already happened months ago…

Jan 12, 2014 – The TKM-Ebola Phase I clinical trial is a randomized, single-blind, placebo-controlled study involving single ascending doses and multiple ascending doses of TKM-Ebola. The study will assess the safety, tolerability and pharmacokinetics of administering TKM-Ebola to healthy adult subjects. Four subjects will be enrolled per cohort. There are four planned cohorts for a total of 16 subjects in the single dose arm, and three planned cohorts for a total of 12 subjects in the multiple dose arm of the trial. Each cohort will enroll three subjects who receive TKM-Ebola, and one who will receive placebo.
[link to investor.tekmirapharm.com]

Anyways, go figure they want to do more human TKM-Ebola trials, even though human tests were put on hold last month due to safety concerns…

While human tests of the company’s treatment, TKM-Ebola, were put on hold last month due to safety concerns, investors scrambled to buy its stock, sending shares up 1.5 percent to $13 in midday Nasdaq trading, and up more than 50 percent over the past fortnight.
[link to news.yahoo.com]

But that bad new isn’t hurting Tekmira’s stock prices at all, which are still skyrocketing as this event unfolds, even with safety issues…

Tekmira shares skyrocket as Ebola outbreak intensifies in Africa
Shares of Canada’s Tekmira Pharmaceutical Corp TKMR.O TKM.TO, which has ambitions of producing the first treatment for the deadly Ebola virus, have skyrocketed as the worst-ever outbreak of the virus intensified in West Africa.
[link to news.yahoo.com]

Because the TMK-Ebola vaccine by Tekmira (which has safety concerns even when not tampered with), due to the current “emergency” situation, will highly-likely get its approval extremely fast-tracked anyways.

‘Fast-track the Ebola drug’: U.S. under pressure to give potentially life-saving medication the green light as experts warn of global pandemic
Campaigners are calling on the Food and Drug Administration (FDA) of the United States to fast-track their authorisation of the TKM-Ebola drug.
[link to www.dailymail.co.uk]
[link to www.change.org]

Anyways for anyone looking at the bigger picture, it appears like they are going to attempt to do what they failed to do in 2009 (due to a Baxter AG fuckup in Europe prior to Phase 2 virus release, which forced them to call that aspect off)… This time however, they expect to be able to declare the long-awaited WHO Pandemic Level 6, allowing for international & national emergency powers to kick in, such as, The Model State Emergency Health Powers Act, The Canadian Pandemic Influenza Plan for the Health Sector, the National Emergency Act, National Security Presidential Directive 51 and so on…

The Model State Emergency Health Powers Act: planning for and response to bioterrorism and naturally occurring infectious diseases
The Model Act is structured to reflect 5 basic public health functions to be facilitated by law: (1) preparedness, comprehensive planning for a public health emergency; (2) surveillance, measures to detect and track public health emergencies; (3) management of property, ensuring adequate availability of vaccines, pharmaceuticals, and hospitals, as well as providing power to abate hazards to the public’s health; (4) protection of persons, powers to compel vaccination, testing, treatment, isolation, and quarantine when clearly necessary; and (5) communication, providing clear and authoritative information to the public.
USA: [link to www.ncbi.nlm.nih.gov]

The Canadian Pandemic Influenza Plan for the Health Sector
Ensure that appropriate legal authorities are in place to allow for the implementation of major elements of a proposed distribution plan. (For example, will P/T laws allow for non-licensed volunteers to administer influenza vaccine? Do P/T laws allow for “mandatory” vaccination of certain groups if vaccination of such groups is viewed by the P/T public health officials as essential to public service?)
Canada: [link to www.phac-aspc.gc.ca]

50 U.S. Code Chapter 34 – NATIONAL EMERGENCIES
SUBCHAPTER I—TERMINATING EXISTING DECLARED EMERGENCIES
SUBCHAPTER II—DECLARATIONS OF FUTURE NATIONAL EMERGENCIES
SUBCHAPTER III—EXERCISE OF EMERGENCY POWERS AND AUTHORITIES
SUBCHAPTER IV—ACCOUNTABILITY AND REPORTING REQUIREMENTS OF PRESIDENT
SUBCHAPTER V—APPLICATION TO POWERS AND AUTHORITIES OF OTHER PROVISIONS OF LAW AND ACTIONS TAKEN THEREUNDER=
[link to www.law.cornell.edu]

National Security Presidential Directive/NSPD #51: National Continuity Policy
This directive establishes a comprehensive national policy on the continuity of Federal Government structures and operations and a single National Continuity Coordinator responsible for coordinating the development and implementation of Federal continuity policies. This policy establishes “National Essential Functions,” prescribes continuity requirements for all executive departments and agencies, and provides guidance for State, local, territorial, and tribal governments, and private sector organizations in order to ensure a comprehensive and integrated national continuity program that will enhance the credibility of our national security posture and enable a more rapid and effective response to and recovery from a national emergency.
[link to fas.org]

Basically when a WHO Pandemic Level 4 Emergency is declared, preparations for countermeasures would be started, which if escalated to a Pandemic Level 6 emergency, would then trigger implementation of mandatory (by law) mass vaccinations of the populous of even not effected areas/countries in what is deemed as “Pandemic Management” (aka the long awaited “phase 2” that Baxter AG fucked up in 2009).

WHO Pandemic Levels
Level 4 = Prepare (preparation)
A reassortant virus is causing community-level outbreaks, meaning there are sustained disease outbreaks in a community. This marks a “significant upwards shift in the risk for a pandemic.” However, a pandemic isn’t necessarily a forgone conclusion.

Level 5 = Mobilize (initiation)
There is human-to-human spread of the virus into at least two countries in one WHO region. Most countries aren’t affected at this stage, but declaration of Phase 5 is a “strong signal that a pandemic is imminent.” There is little time remaining to finish the organization, communication and implementation of the planned mitigation measures.

Level 6 = Sustain (vaccination)
In addition to the countries affected in Phase 5, there are community-level outbreaks in at least one other country in a different WHO region. A global pandemic is occurring.

Just hope people see this event for what it is… and understand what is to come.

The jist of the plan in 2009 was this…

2009 Swine Flu Pandemic
Phase 1 (cover)
1. Release a fairly harmless human-to-human transmittable swine flu strain (H1N1) near the Mexico border.
2. Infect a small number of subjects in China with a non human-to-human transmittable strain of bird flu (H5N1).
3. Overlap both during a natural influenza season (H3N2).
4. Push the need for mass vaccinations by overly hyping the virility of the H1N1 strain being circulated (cause).
Phase 2 (real pandemic)
5. As part of the vaccination program, infect various groups of subjects with a the real Pandemic, a bioengineered hybrid of all 3 (H1N1/H5N1/H3N2), which was to be included in a small percentage of the initial Baxter AG Swine-Flu Vaccine (this is the stage they got caught at just prior to launching and had to call it off, and recall the vaccines in question just prior to being used).
The end result if everything went as planned would of been an airborne human-to-human transmittable hybrid virus (H1N1/H5N1/H3N2), with a ~10-14 day incubation period, and a ~40% mortality rate.
Note: They required the 3 “natural strains (H1N1, H5N1, H3N2) to be active before releasing the weaponized hybrid (H1N1/H5N1/H3N2) so that the bioengineered hybrid once released could be written of as being “naturally created”.

Because of this they had to regroup and tweak/simplify the framework slightly, so that the plan no longer relied on the mass vaccination stage in order to initiate the Phase 2 release… Which brings us to today…

2014 Ebola Epidemic/Pandemic
Phase 1 (cover)
1. Release a standard Ebola-Zaire strain in Guinea.
2. Do it near an area that currently has Lassa active (Nigeria) so that a few weeks later the 2 viruses will overlap in at least 1 area.
Note: Again this is done so that when they release the weaponized hybrid of the 2 (EBOV/LASV) they can say it is “natural created”.
Phase 2 (real pandemic)
3. Release the real Pandemic using a hybrid Ebola/Lassa (EBOV/LASV), to several unwitting subjects inside the Kenema Government Hospital in Sierra Leone.
The end result is an airborne human-to-human transmittable hybrid virus (EBOV/LASV), with a ~9-21 day incubation period, and a ~40% mortality rate.

—
More Context…
—

Baxter: Product contained live bird flu virus (February 27, 2009)
The contaminated product, which Baxter calls “experimental virus material,” was made at the Orth-Donau research facility. Baxter makes its flu vaccine — including a human H5N1 vaccine for which a licence is expected shortly — at a facility in the Czech Republic.
People familiar with biosecurity rules are dismayed by evidence that human H3N2 and avian H5N1 viruses somehow co-mingled in the Orth-Donau facility. That is a dangerous practice that should not be allowed to happen, a number of experts insisted.
Accidental release of a mixture of live H5N1 and H3N2 viruses could have resulted in dire consequences.
While H5N1 doesn’t easily infect people, H3N2 viruses do. If someone exposed to a mixture of the two had been simultaneously infected with both strains, he or she could have served as an incubator for a hybrid virus able to transmit easily to and among people.
That mixing process, called reassortment, is one of two ways pandemic viruses are created.
Thread: Anyone Remember Baxter International? If We Learned Anything From The Swine Flu Dry-Run It Should Be DON’T TAKE THE VACCINE!

Criminal Charges Concerning Bioterrorism Acts and Mass Murder
I am presenting evidence of acts of bioterrorism that are in violation of criminal law of the United States by a group operating within the United States under foreign direction, specifically under the direction of international bankers who control, among other financial institutions, the Federal Reserve, as well as international government organisations, specifically the World Health Organisation, the United Nations and NATO.
…
Evidence is presented that the complex of pharmaceutical companies of Baxter, Novartis and Sanofi Aventis are part of aforeign-based duel purpose bioweapons programme financed by the international criminal syndicate and designed to implement mass murder to reduce the world’s population by as much as 5.5 billion, in the next ten years, to spread terror, to justify forcing people to give up their rights and mass quarantine in FEMA camps.
Thread: Criminal Charges Concerning Bioterrorism Acts and Mass Murder – Jane Burgermeister Dossier – 154 Pages

National Security Study Memorandum 200: Implications of Worldwide Population Growth For U.S. Security and Overseas Interests
Section I – A U.S. Global Population Strategy 74-84
Section II – Action to Create Conditions for Fertility Decline: Population and a Development Assistance Strategy 85-105
A. General Strategy and Resource for A.I.D. Assistance 85-91
B. Functional Assistance Programs to Create Conditions for Fertility Decline 92-102
C. Food for Peace Program and Population 103-105
Section III -International Organizations and other Multilateral Population Programs 106-107
A. UN Organization and Specialized Agencies
B. Encouraging Private Organizations
Thread: Kissinger’s 1974 National Security Study Memorandum 200 (Declassified 1989) – Official US/UN Eugenics Programs

United Nations Agenda 21
The stated goal of Agenda 21 is “achieving sustainable development in the 21st century,” thus the numeral 21 in the document’s title. It strives to help governments meet “the needs of the present without compromising the ability of future generations.”
– [link to sustainabledevelopment.un.org]

Georgia Guidestones
1. Maintain humanity under 500,000,000 in perpetual balance with nature.
2. Guide reproduction wisely — improving fitness and diversity.
3. Unite humanity with a living new language.
4. Rule passion — faith — tradition — and all things with tempered reason.
5. Protect people and nations with fair laws and just courts.
6. Let all nations rule internally resolving external disputes in a world court.
7. Avoid petty laws and useless officials.
8. Balance personal rights with social duties.
9. Prize truth — beauty — love — seeking harmony with the infinite.
10. Be not a cancer on the earth — Leave room for nature — Leave room for nature.